This study aims to investigate the effects of chronic fluoxetine (FLX) treatment on preadipocyte factor-1 (Pref-1) expression in subcutaneous, visceral and brown adipose tissues, and on the size of vacuoles in a dipocytes obtained from the perirenal regions in rats. Twenty-eight Wistar rats were treated with FLX at two different doses and fourteen animals received vehicle. After 40 days of treatment, the subcutaneous, perirenal and interscapular adipose tissues were collected. Pref-1 expression was examined using an immunohistochemical method and the vacuolar area was measured in stained sections. In the low dose FLX group, the size of vacuoles increased both in male and female animals. The high dose of FLX also induced a significant increase of vacuole size, but only in male animals. Neither of the two doses of FLX has significantly affected the Pref-1 expression in any type of adipose tissue.
1. S. Adams, D. Heckard, J. Hassell and L. Uphouse, Factors influencing fluoxetine-induced sexual dysfunction in female rats, Behav. Brain Res. 235 (2012) 73-81; https://doi.org/10.1016/j.bbr.2012.07.029
2. M. Afkhami-Ardekani and H. Sedghi, Effect of fluoxetine on weight reduction in obese patients, Indian J. Clin. Biochem. 20 (2005) 135-138.
3. S. R. Blumenthal, V. M. Castro, C. C. Clements, H. R. Rosenfield, S. N. Murphy, M. Fava, J. B. Weilburg, J. L. Erb, S. E. Churchill, I. S. Kohane, J. W. Smoller and R. H. Perlis, An electronic health records study of long-term weight gain following antidepressant use, JAMA Psychiatry 71 (2014) 889-896; https://doi.org/10.1001/jamapsychiatry.2014.414
4. J. P. Domecq, G. Prutsky, A. Leppin, M. B. Sonbol, O. Altayar, C. Undavalli, Z. Wang, T. Elraiyah, J. P. Brito, K. F. Mauck, M. H. Lababidi, L. J Prokop, N. Asi, J. Wei, S. Fidahussein, V. M. Montori and M. H. Murad, Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis, J. Clin. Endocrinol. Metab. 100 (2015) 363-370; https://doi.org/10.1210/jc.2014-3421
5. C. S. Hudak and H. S. Sul, Pref-1, a gatekeeper of adipogenesis, Front. Endocrinol. 4 (2013) 1-6; https://doi.org/10.3389/fendo.2013.00079
6. S. Caccia, M. Cappi, C. Fracasso and S. Garattini, Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat, Psychopharmacology (Berlin) 100 (1990) 509-514.
7. N. W. Jacobsen, C. H. Hansen, C. Nellemann, B. Styrishave and B. Halling-Sørensen, Effects of selective serotonin reuptake inhibitors on three sex steroids in two versions of the aromatase enzyme inhibition assay and in the H295R cell assay, Toxicol. in Vitro 29 (2015) 1729-1735; https://doi.org/10.1016/j.tiv.2015.07.005
8. B. K. Sun, J. H. Kim, J. S. Choi, S. J. Hwang and J. H. Sung, Fluoxetine decreases the proliferation and adipogenic differentiation of human adipose-derived stem cells, Int. J. Mol. Sci. 16 (2015) 16655-16668; https://doi.org/10.3390/ijms160716655
9. M. Kolcsár, Z. Gáll, I. L. Bíró, L. I. Bába, A. Imre, M. T. Dogaru and O. Martha, Fluoxetine influence on body weight, serum adiponectin level and adipose tissue triglycerides levels in rats, Farmacia 6 (2016) 599-604.
10. A. K. Stunes, J. E. Reseland, O. Hauso, M. Kidd, K. Tommeras, H. L. Waldum, U. Syversen and B. I. Gustafsson, Adipocytes express a functional system for serotonin synthesis, reuptake and receptor activation, Diabetes Obes. Metab. 13 (2011) 551-558; https://doi.org/10.1111/j.1463-1326.2011.01378.x
11. S. Grès, S. Canteiro, J. Mercader and C. Carpéné, Oxidation of high doses of serotonin favors lipid accumulation in mouse and human fat cells, Mol. Nutr. Food Res. 57 (2013) 1089-1099; https://doi.org/10.1002/mnfr.201200681
12. S. Grès, S. Gomez-Zorita, A Gomez-Ruiz and C. Carpene, 5-Hydroxytryptamine actions in adipocytes: involvement of monoamine oxidase-dependent oxidation and subsequent PPARγ activation, J. Neural. Transm. (Vienna) 120 (2013) 919-926; https://doi.org/10.1007/s00702-012-0959-8